Hongmei Song

This inventor holds 14 USPTO granted patents and 42 published patent applications, plus 1 CIPO patent and 6 EPO patents. Top assignees: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Ellipses Pharma Limited. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hongmei Song. Retrieved from https://idiyas.com/inventor/hongmei-song

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14 (Patent Applications = 42)

% Patents Active = 92.9

CIPO Patents = 1 (Patent Applications = 19)

EPO Patents = 6 (Patent Applications = 47)

Average Co-Inventor Count = 11.9

ph-index = 2

Forward Citations = 10(Granted Patents)

Location History:

Chengdu, CN (2016 - 2021)
Sichuan, CN (2022 - 2024)

Company Filing History:

10 out of 26

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

patents

2 out of 3

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

patents

1 out of 6

Ellipses Pharma Limited

Sichuan Kelun-Biotech Biopharmaceuticals Co., Ltd.

patent

where one patent can have more than one assignee

Years Active: 2016-2026

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12668593 - Pyrazole compound and preparation method therefor and use thereof (2026-06-30),

2. 12630557 - Salt and crystal form of pyrimidine compound, and preparation methods therefor (2026-05-19),

3. 12269816 - Benzothiophene compound, preparation method therefor and use thereof (2025-04-08),

4. 12150944 - Use of anti-HER2 antibody-drug conjugate in cancer treatment (2024-11-26),

5. 11903948 - Anti-ErbB2 antibody-drug conjugate and composition thereof, preparation method therefor, and use thereof (2024-02-20),

6. 11266674 - Pharmaceutical composition for tumor treatment or prevention, method, and use thereof (2022-03-08),

7. 11207420 - Cytotoxin and conjugate, uses of same and preparation method therefor (2021-12-28),

8. 11166954 - Dihydropyrimidine compound and preparation method and use thereof (2021-11-09),

9. 11084847 - Polyamide compound and use thereof (2021-08-10),

10. 11045455 - Azetidine derivative, preparation method therefor, and use thereof (2021-06-29),

11. 10899786 - Nucleoside phosphate compound and preparation method and use thereof (2021-01-26),

12. 10696669 - Dihydropyrimidine compound and preparation method and use thereof (2020-06-30),

13. 10159662 - Azetidine derivative, preparation method therefor, and use thereof (2018-12-25),

14. 9518998 - Drug target capturing method (2016-12-13),

Certainly! Here is the article about inventor Hongmei Song:

Title: Unveiling the Innovations of Inventor Hongmei Song

Introduction:

In the bustling city of Chengdu, China, resides the brilliant inventor Hongmei Song, who has made significant contributions in the field of pharmaceutical compositions for tumor treatment and prevention. With an impressive portfolio of 9 patents, Hongmei Song continues to revolutionize the landscape of medical advancements.

Latest Patents:

1. Pharmaceutical composition for tumor treatment or prevention, method, and use thereof: This patent introduces a revolutionary pharmaceutical composition comprising a 4’-thionucleoside phosphamide derivative, offering new possibilities for disease treatment and prevention.

2. Cytotoxin and conjugate, uses of same and preparation method therefor: By developing a method for modifying chimeric antigen receptor-modified T cells, Hongmei Song has paved the way for personalized treatment of tumor-related diseases.

Career Highlights:

Hongmei Song has left an indelible mark in renowned companies such as Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and HitGen, Inc., where his innovative spirit and dedication have shone through. His expertise has been instrumental in driving forward cutting-edge research and development initiatives.

Collaborations:

Throughout his illustrious career, Hongmei Song has collaborated with esteemed colleagues such as Hong Zeng and Lichun Wang, fostering a collaborative environment that nurtures creativity and excellence. Together, they have synergized their efforts to push the boundaries of scientific discovery.

Conclusion:

In conclusion, Hongmei Song's pioneering work in the field of pharmaceutical compositions and tumor treatment stands as a testament to his unwavering commitment to innovation. His patents not only showcase his technical prowess but also underscore his passion for making a positive impact on healthcare. Hongmei Song's journey as an inventor continues to inspire us all to dream, discover, and innovate for a better tomorrow.

Profile summary based on public USPTO records.